Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Braz. j. med. biol. res ; 54(2): e10099, 2021. tab
Article in English | ColecionaSUS, LILACS, ColecionaSUS | ID: biblio-1142582

ABSTRACT

The objective of this study was to analyze the infection rate and drug resistance of Ureaplasma urealyticum (UU) and Mycoplasma hominis (MH) in the genitourinary tract of Chinese patients. From December 2018 to June 2019, vaginal secretion or urinary secretion of outpatients in our hospital were selected for culture and drug sensitivity analysis of Ureaplasma urealyticum and Mycoplasma hominis. In 4082 Chinese samples, 1567 Mycoplasma were detected, a detection rate of 38.39%, among which 1366 cases were UU single positive, accounting for 33.47%, 15 cases were MH single positive, accounting for 0.36%, 186 cases were UU and MH mixed positive, accounting for 4.56%. The most affected age groups were 21-30 years and 31-40 years, accounting for 19.09 and 15.05%, respectively. The results of drug sensitivity showed that doxycycline, minocycline, josamycin, clarithromycin, and roxithromycin were more sensitive to mycoplasma infection. The distribution of Ureaplasma urealyticum and Mycoplasma hominis in the human genitourinary system and their sensitivity to antibiotics is different for sex and age groups.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Ureaplasma urealyticum/drug effects , Ureaplasma Infections/microbiology , Mycoplasma hominis/drug effects , Microbial Sensitivity Tests , China , Ureaplasma urealyticum/isolation & purification , Mycoplasma hominis/isolation & purification , Asian Continental Ancestry Group , Anti-Bacterial Agents/pharmacology
2.
Rev. chil. obstet. ginecol. (En línea) ; 84(1): 49-54, feb. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1003722

ABSTRACT

RESUMEN OBJETIVO: Ureaplasma urealyticum es el agente más frecuentemente aislado en infección intraamniótica. Los macrólidos son los antimicrobianos de primera elección en embarazadas. Se ha descrito el aumento de resistencia, pudiendo limitar las opciones terapéuticas durante la gestación. El propósito del estudio es evaluar susceptibilidad antimicrobiana de Ureaplasma urealyticum aislado en mujeres en edad fértil, que se atienden en Clínica Alemana Temuco, Araucanía, Chile. METODO: Se estudian todas las muestras de orina y flujo vaginal para cultivo de U. urealyticum, de pacientes entre 18 y 40 años, recibidas en el Laboratorio de Microbiología Clínica Alemana Temuco, en período Abril 2013 a Enero 2015. Se procesan las muestras con kit Mycoplasma IST 2 de Biomerieux. En las que resultan positivas, se estudia susceptibilidad a macrólidos, tetraciclinas y quinolonas. RESULTADOS: 426 muestras de orina y flujo vaginal (390 pacientes). 197 pacientes resultaron positivas para U. urealyticum. (50,5%). La susceptibilidad fue 88,4% (174 pctes) a Eritromicina, 87,9% (173 pctes) a Claritromicina y 91,9% (181 pctes) a Azitromicina (NS). 15 de 197 pacientes (7,6%) fueron resistentes a los 3 macrólidos. La susceptibilidad a Quinolonas fue 55,3% a Ciprofloxacino, y 94% a Ofloxacino. El 100% resultó susceptible a Tetraciclinas. CONCLUSIONES: Cerca del 10% de U. urealyticum aislados en nuestra serie son resistentes a macrólidos, contribuyendo a la no erradicación de la infección en tratamientos empíricos. Dentro de ellos, azitromicina aparece con la mayor efectividad. El aumento de resistencia limitará opciones terapéuticas, con gran impacto perinatal en futuro. La vigilancia de susceptibilidad en cada hospital es fundamental para elección terapéutica.


ABSTRACT INTRODUCTION: Ureaplasma urealyticum is the most frequently isolated microorganism in intra-amniotic infection. The macrolides are the first choice antimicrobials for treat this infection in pregnancy. The increasing resistance has been described worldwide, seriously limiting therapeutic options in pregnancy. The aim of the study is to evaluate antimicrobial susceptibility of U. urealyticum aislated in fertile-age women in Clínica Alemana Temuco, Araucania region, Chile. METHOD: Urine and vaginal samples were analyzed for U. urealyticum, from every 18 to 40 years old patients, received at Microbiology Laboratory of Clínica Alemana Temuco, between April 2013 to January 2015. The samples are processed with Mycoplasma IST 2 kit of Biomerieux. If they became positives, susceptibility to macrolides, tetracyclines and quinolones was studied. RESULTS: 426 urine and vaginal samples were collected (390 patients). 197 patients were positive for U. urealyticum (50.5%). The susceptibility was 88.4% (174 pts) to Erythromicyn, 87.9% (173 pts) to Clarithromycin and 91.9% (181 pts) to Azithromycin (NS). Resistance to all macrolides was observed in 15 out of 197 patients (7.6%). The susceptibility to Quinolones was 55.3% to Ciprofloxacin, and 94% to Ofloxacin. The 100% was susceptible to Tetracyclines. DISCUSSION: Near to 10% of isolated Ureaplasma spp in our serie were resistant to some macrolide, being a factor for failing to eradicate the infection in empirical treatment. Azithromycin was the most effective. The increasing resistance will limit therapeutic options, with great perinatal impact in the future. Susceptibility surveillance in each hospital is very important for therapeutic options.


Subject(s)
Humans , Female , Adolescent , Adult , Young Adult , Ureaplasma urealyticum/drug effects , Anti-Bacterial Agents/pharmacology , Tetracycline/pharmacology , Urine/microbiology , Urogenital System/microbiology , Microbial Sensitivity Tests , Erythromycin/pharmacology , Ureaplasma urealyticum/isolation & purification , Azithromycin/pharmacology , Quinolones/pharmacology , Macrolides/pharmacology , Drug Resistance, Bacterial
3.
Yonsei Medical Journal ; : 1271-1275, 2016.
Article in English | WPRIM | ID: wpr-79764

ABSTRACT

Mycoplasma hominis (M. hominis) and Ureaplasma urealyticum (U. urealyticum) are important opportunistic pathogens that cause urogenital infections and complicate pregnancy. The aim of this study was to investigate the prevalence, effects on pregnancy outcomes, and antimicrobial susceptibilities of M. hominis and U. urealyticum. We tested vaginal swabs obtained from 1035 pregnant women for the presence of genital mycoplasmas between June 2009 and May 2014. The laboratory and clinical aspects of genital mycoplasmas infection were reviewed retrospectively, and the identification and antimicrobial susceptibility of genital mycoplasmas were determined using the Mycoplasma IST-2 kit. A total of 571 instances of M. hominis and/or U. urealyticum were detected. Of them, M. hominis was detected in two specimens, whereas U. urealyticum was detected in 472 specimens. The remaining 97 specimens were positive for both M. hominis and U. urealyticum. Preterm deliveries were frequently observed in cases of mixed infection of M. hominis and U. urealyticum, and instances of preterm premature rupture of membrane were often found in cases of U. urealyticum. The rates of non-susceptible isolates to erythromycin, empirical agents for pregnant women, showed increasing trends. In conclusion, the prevalence of M. hominis and/or U. urealyticum infections in pregnant women is high, and the resistance rate of antimicrobial agents tends to increase. Therefore, to maintain a safe pregnancy, it is important to identify the isolates and use appropriate empirical antibiotics immediately.


Subject(s)
Adolescent , Adult , Anti-Bacterial Agents/pharmacology , Female , Humans , Infant, Newborn , Microbial Sensitivity Tests , Middle Aged , Mycoplasma Infections/drug therapy , Mycoplasma hominis/drug effects , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Pregnancy Outcome , Prevalence , Retrospective Studies , Ureaplasma Infections/drug therapy , Ureaplasma urealyticum/drug effects , Young Adult
4.
Indian J Med Microbiol ; 2011 Jul-Sept; 29(3): 288-292
Article in English | IMSEAR | ID: sea-143836

ABSTRACT

Purpose: To develop Taqman fluorescence quantitative polymerase chain reaction (PCR) method for investigating the characteristics of the distributions of Ureaplasma urealyticum (UU) biovars and to explore the relationship between UU biovars and antimicrobial resistance. Materials and Methods: By the method of culture, Ureaplasma species were detected. Taqman fluorescence quantitative PCR for detecting UU biovars were developed and UU clinical isolates were detected to distinguish biovars. The broth micro-dilution susceptibility testing methods were used to determine UU susceptibility. Results: By Taqman PCR method, UU biovars was successfully detected. Of 126 samples, biovar 1 was found in 73 (57.94%). There was a statistical difference between genital-urinary tract infection group and asymptomatic group (P<0.05). In the region, UU biovar 1 to 9 kinds of agents kept higher susceptibility rates, but biovar 2 maintained higher susceptibility rates only to tetracyclines. Compared with biovar 1, UU biovar 2 resistance rates to 7 kinds of agents were higher (P<0.05). Conclusions: (1) Our new established Taqman PCR method is a useful tool for screening UU biovars. (2) UU biovar 1 predominated in asymptomatic population; whereas in genital-urinary tract infection population UU biovar 2 had a higher proportion. (3) The characteristics of drug resistance were different between UU biovars. Overall, both two biovars remained higher susceptibility rates to tetracyclines. A majority of biovor 1 strains were sensitive to macrolides and quinolones; while only a small number of biovar 2 strains kept sensitive to roxithromycin and quinolones, a large proportion of biovar 2 strains were found in intermediate ranges.


Subject(s)
Bacterial Typing Techniques , Drug Resistance, Bacterial , Female , Humans , Male , Microbial Sensitivity Tests , Polymerase Chain Reaction/methods , Ureaplasma urealyticum/classification , Ureaplasma urealyticum/drug effects , Ureaplasma urealyticum/genetics
5.
Rev. chil. infectol ; 17(supl.1): 66-71, 2000. tab, graf
Article in Spanish | LILACS | ID: lil-269446

ABSTRACT

La etiología de la uretitis no gonocóccica trasciende las infecciones por chlamydia trachomatis y ureaplasma urealyticum. otros agentes etiológicos comunes son responsables de aproximadamente 20 por ciento de los casos y en un tercio no se precisa una etiología. Por esta situación se requiere de una nueva terminología para caracterizar mejor esta entidad. Test de amplificación genómica aplicados a la secreción uretral u orina son nuevas herramientas para un diagnóstico precoz de chlamydia trachomatis. El diagnóstico precoz es muy importante para evitar complicaciones y secuelas, especialmente infertilidad en mujeres, mediante un tratamiento oportuno y adecuado. Azitromicina, 1g oral, en dosis única es un avance significativo en el tratamiento de la uretritis causada por clamidias


Subject(s)
Humans , Chlamydia trachomatis/isolation & purification , Ureaplasma urealyticum/isolation & purification , Urethritis/diagnosis , Azithromycin/therapeutic use , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/pathogenicity , Gene Amplification , Ureaplasma urealyticum/drug effects , Ureaplasma urealyticum/pathogenicity , Urethritis/drug therapy , Urethritis/etiology , Urine/microbiology
6.
Rev. chil. tecnol. méd ; 15(1/2): 725-30, 1992. tab
Article in Spanish | LILACS | ID: lil-152920

ABSTRACT

Se realizó estudio microbiológico de raspado uretral de 142 pacientes de sexo masculino que consultaron al policlínico de Venéreas del Hospital Base de Valdivia durante 1989, los cuales fueron enviados al Instituto de Microbiología Clínica de la Universidad Austral de Chile con diagnóstico clínico de uretritis. La prevalencia de Uretritis Gonocócicas (UG) y Uretritis no Gonocócica (UNG) fue de un 50 por ciento para ambos tipos. U. urealyticum fue aislado en el 38 por ciento de los casos de UG y en el 59.2 por ciento de las UNG. Además se evaluó la efectividad del tratamiento de las uretritis por U. urealyticum con tetraciclina en base a tres esquemas: 2g/día durante 7 días, 2 g/día durante 14 días y 2 g/dia durante 21 días. Por este motivo, se seleccionaron 59 pacientes con uretritis por U. urealyticum, obteniéndose un 57,6 por ciento de éxito en el total de los pacientes estudiados. La mayor efectividad en el tratamiento fue para el esquema de 21 días (77.8 por ciento) además a medida que aumentó la edad de los pacientes la efectividad fue disminuyendo y cuando U. urealyticum se encontró asociado a otros microorganismos se obtuvo un mayor éxito en los tratamientos


Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , Ureaplasma urealyticum/isolation & purification , Urethritis/microbiology , Drug Administration Schedule , Erythromycin/administration & dosage , Marital Status , Neisseria gonorrhoeae/isolation & purification , Tetracycline/administration & dosage , Ureaplasma urealyticum/drug effects , Ureaplasma urealyticum/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL